Navigation Links
Best Practices Document on Cryoablation Posted on Website of American Urological Association
Date:9/23/2008

IRVINE, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that the American Urological Association (AUA) has for the first time posted on its website the organization's official "best practice" document on cryoablation for prostate cancer, covering primary, salvage and focal cryoablation, also called cryosurgery. The AUA posting of these clinical guidelines is an acknowledgement of the important advances made in the technology of cryoablation, a minimally invasive treatment for prostate cancer that freezes cancerous tumors to destroy them, said Endocare Chairman, President and CEO Craig T. Davenport.

"This is a principled and unbiased assessment of the effectiveness of cryoablation for treating prostate cancer made by the country's most prestigious association of urologists," Davenport said. "The AUA panel that did the assessment looked at all the published studies of cryoablation and came to the conclusion that it is a valuable treatment that should be considered by prostate cancer patients. The publication of these guidelines helps to place cryoablation more squarely in the mainstream of prostate cancer treatments."

The 51-page document, titled "Best Practice Policy Statement on Cryosurgery for the Treatment of Localized Prostate Cancer" and officially adopted at the recent AUA national conference, specifically notes the "seven-to-eight-year biochemical disease free results of cryosurgery. The literature reports that the morbidity profile associated with cryosurgery has improved in all aspects, including continence, rectal/urethral fistula formation, urethral sloughing, and potency in association with the technological advances over the last 10 to 15 years."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

matt@allencaron.com len@allencaron.com

http://www.allencaron.com http://www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

http://www.endocare.com


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
2. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
3. New Study Recognizes Halogen Customer for Best Practices in Employee Performance and Talent Management
4. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
5. Genstruct and Sirtris Pharmaceuticals Win Bio-IT Worlds Best Practices Award
6. Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry
7. Web-Conferences by Best Practices, LLC for July 2008
8. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
9. First documented case of pest resistance to biotech cotton
10. Researchers Document Rapid, Dramatic Reverse Evolution in the Threespine Stickleback Fish
11. Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
Breaking Biology Technology:
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):